CR11812A - Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso - Google Patents

Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso

Info

Publication number
CR11812A
CR11812A CR11812A CR11812A CR11812A CR 11812 A CR11812 A CR 11812A CR 11812 A CR11812 A CR 11812A CR 11812 A CR11812 A CR 11812A CR 11812 A CR11812 A CR 11812A
Authority
CR
Costa Rica
Prior art keywords
meningococo
vesicula
multivalent
vaccine
manufacturing
Prior art date
Application number
CR11812A
Other languages
English (en)
Inventor
David Zollinger Wendell
Donets Mikhail
Schmiel Deborah
Ionin Boris
Marques Ryan
Ellen Moran Elizabeth
Original Assignee
U S A As Represented By The Secretary Of The Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S A As Represented By The Secretary Of The Army filed Critical U S A As Represented By The Secretary Of The Army
Publication of CR11812A publication Critical patent/CR11812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente tecnología presenta una combinación de vesículas nativas de la membrana externa (NOMV) de por lo menos una cepa genéticamente modificada de la Neisseria que proporciona inmunidad protectora contra la enfermedad del meningococo, de preferencia la enfermedad del meningococo del subtipo B.
CR11812A 2008-05-30 2010-11-25 Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso CR11812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5746208P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
CR11812A true CR11812A (es) 2011-07-06

Family

ID=41444870

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11812A CR11812A (es) 2008-05-30 2010-11-25 Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso

Country Status (19)

Country Link
US (2) US9387239B2 (es)
EP (1) EP2296699A4 (es)
JP (2) JP5723768B2 (es)
KR (1) KR20110053314A (es)
CN (1) CN102105166A (es)
AU (1) AU2009262893B2 (es)
BR (1) BRPI0913268A2 (es)
CA (1) CA2726465A1 (es)
CO (1) CO6341569A2 (es)
CR (1) CR11812A (es)
DO (1) DOP2010000364A (es)
EC (1) ECSP10010723A (es)
IL (1) IL209660A0 (es)
MX (1) MX2010012999A (es)
NZ (1) NZ589812A (es)
RU (1) RU2477145C2 (es)
UA (1) UA99659C2 (es)
WO (1) WO2009158142A1 (es)
ZA (1) ZA201008548B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580072A (zh) 1999-05-19 2012-07-18 诺华疫苗和诊断有限公司 组合式奈瑟球菌组合物
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN103002910A (zh) * 2010-03-10 2013-03-27 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
HRP20210242T4 (hr) * 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CA2846290A1 (en) 2011-08-31 2013-03-07 Children's Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
US9657297B2 (en) * 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
MX2019006105A (es) * 2016-11-25 2019-08-21 Glaxosmithkline Biologicals Sa Conjugados de vmen-antigeno y uso de los mismos.
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107151270B (zh) * 2017-03-22 2018-07-31 武汉博沃生物科技有限公司 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用
CN113151354B (zh) * 2021-03-22 2022-03-08 中国农业科学院兰州兽医研究所 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US7112332B1 (en) * 1992-10-08 2006-09-26 The United States Of America As Represented By The Secretary Of The Army Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
DK1154791T3 (da) 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
ES2507100T3 (es) * 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
PL399492A1 (pl) * 2002-08-02 2012-11-19 Glaxosmithkline Biologicals S.A. Szczepionka
CU23377A1 (es) * 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
KR101270838B1 (ko) * 2004-05-11 2013-07-04 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 폭스겐트존하이트 벨지인 엔 스포츠 보조제로서의 나이세리아 메닌자이티디스 ＩｇｔＢ ＬＯＳ
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
JP5275982B2 (ja) * 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン

Also Published As

Publication number Publication date
CN102105166A (zh) 2011-06-22
UA99659C2 (uk) 2012-09-10
BRPI0913268A2 (pt) 2016-03-15
ECSP10010723A (es) 2011-05-31
JP5723768B2 (ja) 2015-05-27
JP2015061870A (ja) 2015-04-02
AU2009262893A9 (en) 2015-05-21
EP2296699A1 (en) 2011-03-23
NZ589812A (en) 2012-08-31
KR20110053314A (ko) 2011-05-20
ZA201008548B (en) 2012-06-27
JP2011521976A (ja) 2011-07-28
AU2009262893A1 (en) 2009-12-30
RU2477145C2 (ru) 2013-03-10
US20110182942A1 (en) 2011-07-28
US9387239B2 (en) 2016-07-12
IL209660A0 (en) 2011-02-28
US20170100471A1 (en) 2017-04-13
WO2009158142A1 (en) 2009-12-30
CO6341569A2 (es) 2011-11-21
AU2009262893B2 (en) 2015-05-21
EP2296699A4 (en) 2013-11-13
RU2010153658A (ru) 2012-08-10
DOP2010000364A (es) 2011-07-15
CA2726465A1 (en) 2009-12-30
MX2010012999A (es) 2012-03-07

Similar Documents

Publication Publication Date Title
CR11812A (es) Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso
BRPI0815008B8 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CO6362045A2 (es) Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
CL2016001235A1 (es) Cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados-formulaciones y usos (divisional solicitud 467-2014).
BRPI0911851A2 (pt) cápsula selada para conter ingredientes para bebidas e que possui uma membrana no lado da entrada.
CL2011000513A1 (es) Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina.
CL2014002415A1 (es) Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11).
AR078247A1 (es) Vacuna de pcsk9
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
CA2763359C (en) New human rotavirus strains and vaccines
BR112013030392A2 (pt) dispositivo de manutenção de pressão para a realização de peças compósitas por injeção de resina e processo associado
AR101225A1 (es) Vacunas de meningococos
BR112015001892A2 (pt) cocleados feitos com fosfatidilserina de soja
BR112013025424A2 (pt) processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica
CL2011001284A1 (es) Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x
CL2015001803A1 (es) Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11)
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
UA100710C2 (ru) Композиция для индукции иммунной реакции против вируса bluetongue (btv) у животного
ECSP14005917A (es) Preparaciones que comprenden emodépsido amorfo
WO2010101750A3 (en) Attenuated salmonella enterica serovar paratyphi a and uses thereof
BRPI0918226A2 (pt) composição imunogênica, método para produzir uma composição imunogênica, método para elicitar uma resposta imune contra neisseria, uso da composição imunogênica, e, vacina
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria